ClinicalTrials.gg
CompletedNCT01055691Updated Jun 1, 2012

A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets

A Phase 1 interventional study of Dapagliflozin/Metformin and Dapagliflozin in Healthy Volunteers, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-01.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary objective of the study is to establish if the same amount of drug is absorbed into the blood after ingesting a combination dapagliflozin/metformin tablet vs. the individual dapagliflozin tablet and individual metformin tablet.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • healthy volunteers
  • bioequivalence
  • dapagliflozin
  • metformin
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female healthy volunteers must be (cessation of menses >1year), be surgically sterile (documented) or hysterectomy or on abstinence
  • Have normal physical exam, vital signs (ECG) findings, and laboratory values

Exclusion criteria

Exclusion Criteria:

  • Use of prescription medication for a chronic or acute medical condition within 3 weeks of randomization
  • History of allergy to metformin
  • Previous participation in an AstraZeneca (AZ) or BristolMyers-Sqibb dapagliflozin study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    1

    Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet

    Drug: Dapagliflozin/Metformin · Drug: Dapagliflozin · Drug: Metformin

  • Experimental
    2

    Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets

    Drug: Dapagliflozin/Metformin · Drug: Dapagliflozin · Drug: Metformin

  • Experimental
    3

    Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet

    Drug: Dapagliflozin/Metformin · Drug: Dapagliflozin · Drug: Metformin

  • Experimental
    4

    Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets

    Drug: Dapagliflozin/Metformin · Drug: Dapagliflozin · Drug: Metformin

Interventions

  • DrugDapagliflozin/Metformin

    Drug pages: Dapagliflozin · Metformin

    Fixed dose combination dapagliflozin/metformin IR tablet 2.5 mg/850 mg Oral Single dose

  • dapagliflozin tablet 2.5 mg Oral Single dose

  • metformin IR tablet 850 mg Oral Single dose

    Also known as: Glucophage

  • DrugDapagliflozin/Metformin

    Drug pages: Dapagliflozin · Metformin

    Fixed dose combination dapagliflozin/metformin IR tablet 5 mg/1000 mg Oral Single dose

  • dapagliflozin tablet 5 mg Oral Single dose

  • metformin IR tablet 1000 mg Oral Single dose

    Also known as: Glucophage

06

What researchers measure

Primary outcomes

  1. bioequivalence will be demonstrated if the 90% confidence interval (CI) for the formulation effect is contained within the interval of 0.8000-1.2500 for AUC(0-t), AUCinf and Cmax with respect to both dapagliflozin and metformin.

    Time frame: Immediately prior to administration of the investigational product (IP). After intake of IP PK blood samples will be drawn every 15 minutes for the first hour, every 30 minutes for the second hour and every hour up to 72 h after intake of IP.

Secondary outcomes

  1. To examine the safety and tolerability of the combination of dapagliflozin and metformin.

    Time frame: Throughout study (for 4 days in each period and a follow-up visit ~6 days later)

07

Study locations

1 site
  • Research Site
    Berlin, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2010
First posted
Jan 26, 2010
Start
Jan 2010
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Last update
Jun 1, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01055691
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 26, 2010
Start date
Jan 2010
Primary completion
Apr 2010
Completion
Apr 2010
Last update
Jun 1, 2012

Study contacts

Georg Golor, M.D.
principal investigator · Parexel
Thomas Koernicke
study director · Parexel

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dapagliflozin · Metformin

Start the discussion